New York, NY March 13, 2024 –(PR.com)– TrialX & The University of Iowa and Olive View Medical Center, University of California, Los Angeles are proud to announce the release of the SAYSTOP Study App, developed for a research study titled “Study of Antibiotics You Stop for Treatment Of Pyelonephritis (SAYSTOP)” led by the University of Iowa and the Olive View Medical Center, University of California, Los Angeles. This app will enable study participants to track and manage their antibiotic usage and report their daily symptoms with ease.
Antibiotic resistance is a pressing global health issue, exacerbated by the rampant overuse and misuse of antibiotics. Brett Faine, PharmD, MS, of the Department of Emergency Medicine, at the University of Iowa and David Talan, MD of the Department of Emergency Medicine at the University of California, Los Angeles are investigating if it is safe for patients to stop their antibiotics when they feel better compared to completing all their antibiotic pills for urinary tract infections (UTI). The University of Iowa and University of California, Los Angeles selected TrialX to develop a user-friendly mobile application tailored for remote data collection for this clinical study.
During the study, participants will receive medications that will come in two separate blister packs for the treatment of their UTI, from which they will make a switch during the study, while tracking symptoms and antibiotic intake. Additionally, the SAYSTOP App will provide reminders to complete surveys, record dosing and any side effects.
“We believe that technology plays a pivotal role in addressing challenges related to clinical trials and the SAYSTOP Study App is a testament to that belief,” said Brett Faine, the co-principal investigator, and “Through this collaboration with TrialX, we hope to gather valuable insights into antibiotic usage patterns and ultimately develop strategies to mitigate the spread of antibiotic resistance.”
“We are thrilled to partner with the University of Iowa and University of California, Los Angeles on this critical research initiative,” said Paul Donnelly, CSO, TrialX.” The SAYSTOP Study App represents a significant step forward in the fight against antibiotic resistance. By harnessing the power of decentralized clinical trial technology, we aim to empower clinical research investigators to simplify and accelerate their study data collection to discover useful insights that guide future strategies in healthcare.
The SAYSTOP Study App is available for download on both iOS and Android devices. To learn more about the research study at the University of Iowa, visit uiowa.edu.
About TrialX
TrialX is a clinical research and space health informatics company headquartered in New York City. From launching the first clinical trials app on Google Health in 2008, to powering online patient recruitment and research data collection for space missions, TrialX is on a mission to facilitate One Billion Health Research Contributions. Through innovative technology and a commitment to enhancing patient outcomes, TrialX bridges the gap between patients and researchers, fostering collaboration and propelling medical innovation. TrialX products include an award-winning patient recruitment management platform), a remote research data collection (ePRO/eCOA) platform and an online talk show, all designed to facilitate collection, analysis, and dissemination of clinical research data across web, mobile or stand-alone devices. TrialX products are used by Top 5 Pharma and other clinical trial sponsors, leading academic medical centers such as the University of Pennsylvania, New York Langone School of Medicine, Indiana University CTSI, Northwestern University and patient advocacy groups such as the Michael J. Fox Foundation for Parkinson’s Research, Alzheimer’s Association and the Global Lyme Alliance. To learn more, visit https://trialx.com/.
Contact Information:
TrialX
Shweta Mishra
212-537-6944
Contact via Email
www.trialx.com
Read the full story here: https://www.pr.com/press-release/907873
Press Release Distributed by PR.com
Source: PR.com
